OPEN ACCESS

Saudi Journal of Biomedical Research

Abbreviated Key Title: Saudi J Biomed Res
ISSN 2518-3214 (Print) |ISSN 2518-3222 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

Review Article

Microfluidics in Biomedical Research: Prospects, Limitations and Future Direction

Dr Sharique Ahmad[1*], Dr Ashish Singh[2], Dr Waseem Raza[3], Dr Raushan Kumar[4], Dr Fardeen Zaidi[5]

[1]Professor, Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow, Uttar Pradesh, India-226003
[2]Dr Lalji Singh Research Centre, Kalwari Sherwan, Jaunpur, Uttar Pradesh, India- 222131
[3]Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow, Uttar Pradesh, India-226003
[4]Department of Biochemistry, University of Allahabad, Science Faculty, Old Katra, Allahabad, Uttar Pradesh, India- 211002
[5]Junior Resident, Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow, Uttar Pradesh, India-226003

DOI: https://doi.org/10.36348/sjbr.2025.v10i10.002 | **Received:** 09.08.2025 | **Accepted:** 07.10.2025 | **Published:** 08.10.2025

***Corresponding author:** Dr Sharique Ahmad
Professor, Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow, Uttar Pradesh, India-226003

Abstract

Microfluidics is the science and technology of manipulating minute fluid volumes within micro-sized channels. It is an interdisciplinary technology that integrates physics, chemistry, biology, materials science, and microengineering, offering transformative potential for biomedical research. Recent innovations in the field of microfluidics such as organ-on-chip devices, droplet-based assays, 3D bioprinting, integration with artificial intelligence and CRISPR technologies have accelerated the development of physiologically close models and personalized medicine approaches. This review comprehensively examines the emerging field of microfluidics, including its design, principles, fabrication techniques, and commonly used materials. Moreover, also highlights the key applications in stem cell culture, organ-mimicking systems, cancer and infectious disease research, drug discovery, and genome editing. Furthermore, it also compares with traditional methods, outlines the current challenges, along with future directions that emphasize smart, adaptive platforms for real-time monitoring and automated control.

Keywords: Microfluidics, Organ-On-Chip, Disease Modelling, Drug Discovery.

1. INTRODUCTION

Microfluidics is the rapidly growing and exciting area of science that focuses on how we control and move tiny amounts of fluids through extremely small channels, often thinner than a human hair. According to the George Whitesides, it's the science and technology of systems that handle incredibly small volumes of liquid using micro-sized pathways. The combination of many fields like physics, chemistry, biology, fluid mechanics, microelectronics, and materials science make it so powerful in tool in current time. This combination provide ability to shrink laboratory functions onto tiny chips known as microfluidics. This becoming a game-changer in biomedical research by offering more precise, faster, and automated ways to study and work with cells, tissues, and even entire organs [1].

The story of microfluidics started when scientists tried to combine techniques from microelectronics and bioanalytical chemistry. A key breakthrough came in 1979, when Terry and colleagues developed a gas chromatograph on a silicon chip, one of the earliest known examples of using micro-machining for fluid control. In the early 1990s, the concept of micro-Total Analysis Systems (μTAS) began to take shape, currently known as "lab-on-a-chip" and "organ-on-a-chip" devices. In 1998, George Whitesides and their team introduced a rapid and affordable method of making microfluidic devices by using a soft, transparent material called PDMS. This earlier breakthrough opened the door to many new possibilities in fluidics. After then, the field has expanded continuously with innovations like digital microfluidics, low-cost paper-based chips, and even 3D printing of microstructures [2, 3].

Microfluidic platforms can be composed from many different materials such as glass, silicon, paper, and various polymers. These are designed into microscale channels, valves, and chambers which have capability of mixing, filtering, separating, or detecting

substances, all within a small, portable system. Depending on their nature of utilization, these systems may be called lab-on-a-chip, organ-on-a-chip, or microreactors. Their flexibility opens the door for a wide range of biomedical applications such as disease diagnostics, drug testing, single-cell analysis, tissue engineering, and even modelling how diseases behave inside the body [4].

Use of microfluidics in cancer research is one of the most exciting and fast-growing areas, making difference in cancer research. These small, chip-like devices are able pick-up cancer-related signs, or biomarkers, from the body fluids like blood or saliva. They can also find cancer cells that have reach into the bloodstream. Besides it helps to make tiny particles that deliver medicine directly into the cancer cells and also mimic the tumors natural environments. This helps researchers to understand how different treatments like chemotherapy, targeted drugs, or gene therapy might work in conditions that closely resemble real life. In long run, it could make cancer research more personal and effective [5].

Recent advances have pushed microfluidics into a whole new era, where it combined with tools like artificial intelligence, high-resolution microscopy, robotics, and 3D bioprinting. It allows scientists to automate the whole experiments, create custom-designed microenvironments, and observe each cell in real time. However, there are many challenges remains to be address such as selection of best materials, streamlining processes, and scaling up manufacturing process. We continued tried to integrate these systems with smart technologies like artificial intelligence, we further advance in detection and treatment of disease.

2. Design Principles and Fabrication Techniques

Selection of appropriate materials and manufacturing techniques is crucial to the design and construction of microfluidic devices. Paper-based, glass-based, and PDMS-based microfluidics are examples of common platform for the microfluidic devices. PDMS is extensively used in microfluidics system because of its low cost, optical clarity, gas permeability, and ease of molding. Glass use is perfect for optical detection, high-temperature reactions, and chemical resistance. Paper-based systems also provide affordable, simple, and perfect for point-of-care diagnostics, especially in resource-limited settings [6].

Fabrication methods in microfluidics vary depending on the type of material used. Soft lithography is the most common technique for PDMS and polymer devices because of its accuracy and cost-effectiveness [7]. However, each material and used technique has its advantages and challenges. For example, PDMS is unsuitable for many organic solvents, while glass is expensive and labour-intensive to shape. Paper, while cheap and biodegradable, they have lack of mechanical strength when wet. So, selection of right combination of material and fabrication technique is crucial for building reliable, functional microfluidic systems tailored to biomedical applications.

Table 1: Commonly used material, key benefits and limitations

Material	Key Benefits	Limitations	Reference
Metals (Al, Cu, Fe)	Durable, high-pressure/temperature resistant, easy to clean	Poor for optical use, limited chemical compatibility	[8]
Silicon	Chemically stable, easy to fabricate, flexible design	Opaque, fragile, expensive	[9]
Glass	Transparent, biocompatible, chemically inert	Costly, labour-intensive fabrication	[10]
Ceramics	High temp and chemical resistance	Brittle, difficult integration	[10]
Polymers (e.g., PDMS, PMMA)	Cheap, easy molding, transparent	Some are porous or absorb solvents (e.g., PDMS)	[11]
Fluoropolymers (Teflon)	Resistant to chemicals, high heat tolerance	Difficult to pattern; limited elasticity	[12]
COCs/COPs	Chemically resistant, low water absorption, good optical clarity	Still under research for broader use	[13]
Epoxy resins	High resolution, stable, transparent	Expensive	[14]
Hydrogels	Mimic ECM, great for 3D cell culture	Mechanically weak, not ideal for full-chip structures	[15]
Paper	Cheap, easy to use, no equipment needed	Weak when wet, low optical clarity	[16]

3. Application of Microfluidics in Different Areas of Biomedical Research

3.1. Microfluidics in Stem Cell Culture and Single-Cell Sequencing

Over the past few years, microfluidic systems significantly gained attention. They reshaped the approach in research of stem cell biology and single cell analysis. By creating tiny, well-controlled environments that closely resembles to the body's natural conditions, these platforms can offer insights that often difficult to achieve with conventional cell culture methods.

In the area of stem cell research, microfluidic devices provide scientists to ability to adjust key

conditions, such as nutrient gradients, fluid shear, and biochemical signals. These platforms can also shape the 3D cultures, whether encapsulate in hydrogels or grown as scaffold-free assemblies, creating a body's natural extracellular matrix like environment. This makes them valuable tool in tissue engineering and developmental biology, where able to observe changes in real time [17].

In parallel, microfluidics has also revolutionized impact on single-cell RNA sequencing (scRNA-seq) by enabling high-throughput, cost-effective analysis of individual cells. Techniques like Drop-Seq and inDrop depend on droplet-based microfluidics, encapsulate the single cells with barcoded beads in nanolitre droplets. This setup allows each cell's RNA to be separately captured and analysed, reveals insights into cellular heterogeneity, rare populations, and gene expression patterns in complex tissues [18].

Taken together, these advances in microfluidic systems have made indispensable tools in precision medicine, drug discovery, regenerative biology, and cellular-level diagnostics, marking a new era in biomedical research.

3.2. Microfluidics in Organ-on-Chip Technologies

Organ-on-chip technologies represent a significant jump in the field of biomedical engineering, allowing scientists to recreate the microarchitecture and dynamic functions of human organs on a small, chip-sized platform. These systems integrate living cells within microfluidic devices, which simulate the mechanical, chemical, and physiological responses of actual tissues, deepen our understanding in complex human body systems.

For example, a heart-on-chip reproduce the contractile behaviour and electrical signaling of cardiac tissues. By embedding heart muscle cells into elastomeric microchannels that mimic blood flow and heartbeat patterns, researchers can study arrhythmias, drug cardiotoxicity, and personalized heart disease models in real time, leading to safer drug development [19]. Similarly, lung-on-chip models able to recreate the alveolar-capillary interface, enabling cyclic stretching and airflow to simulate breathing. These systems are helpful in studying respiratory infections (like COVID-19), inhalation toxicology, and drug delivery across the air-blood barrier [20].

The tumor-on-chip platform is another vital development, designed to understand the tumor microenvironment, including vascularization, oxygen gradients, and interactions with immune system. These devices allow researchers to track cancer cell behaviour, metastasis, and drug response under close physiological conditions, thus enabling more accurate screening of anticancer therapies [21].

Thus, organ-on-chip devices uses as a predictive tool for drug discovery, toxicity testing, and disease modelling by creating *in vivo* like conditions, including mechanical forces, 3D architecture, and multi-cell interactions. They provide more clinically appropriate data, reduce need for animal studies, opening the door to precision and personalized medicine.

3.3. Microfluidics in Disease Modelling

Microfluidic systems provide an environment, closely resembles to complex human physiology, provides model human diseases in lab settings. These tiny instruments provide effective platform for researching how diseases develop, progress, and react to treatments.

In the context of cancer study, microfluidic "tumor-on-chip" platforms, enabled researchers to replicate key stages of metastasis such as invasion, intravasation, and colonization of distant tissues. These models combine cancer cells, stromal cells, extracellular matrix, and even immune components which helps in study of tumor cells interaction with their surroundings. Recent innovations have introduced multi-organ microfluidic chips help to understand that how circulating tumor cells travel from the primary site to distant organs like the bone, liver, or lungs. Such systems deepen our understanding in organ-specific metastasis and for testing targeted anti-cancer drugs under near-physiological conditions.

In case of neurological disorders like Alzheimer's and Parkinson's, brain-on-chip systems provide a dynamic platform for research, where neurons, glial cells, and even blood-brain barrier components can be grown together. These advancements allow researchers to initiate the deposition of amyloid-beta plaques or monitor the degeneration of dopamine-producing neurons in real time study.

Microfluidics also provide platform in infectious diseases modelling. Lung-on-chip devices were used to investigate how the SARS-CoV-2 virus infects human lung epithelial cells and causes inflammatory responses during the COVID-19 pandemic. These chips stimulate the air-blood barrier and mechanical breathing motions, providing insights into viral transmission and drug testing. In tuberculosis research, granuloma-on-chip models replicate the immune-rich and hypoxic environments of TB lesions, helping to investigate the behaviour of Mycobacterium tuberculosis and their host's immune response [19].

Thus, microfluidic platforms provide a more scalable, physiologically relevant as well as ethically more suitable substitute for animal models. They are essential to contemporary biomedical research because of their capacity to replicate organ-level function and disease-specific microenvironments, particularly for

drug screening, personalized medicine, and mechanistic disease studies.

3.4. Microfluidics in Drug Discovery and Toxicology

Drug discovery is very expensive and time-consuming process. Traditional way used high-throughput screening (HTS) relies on large well-plates, robotics, and static 2D cell cultures system to test thousands of compounds. These traditional systems unable to mimic the complex, dynamic environment of the human body. Without these, cell behaviour and drug responses in such models might be differ from actual systems.

In contrast to traditional system, microfluidic systems offer a more advanced approach by providing precise control over the cell microenvironment. They operate at very small amount which reduces the reagent use and cost, while supporting both 2D and 3D cultures such as spheroids and organoids. Features like droplet-based handling, parallel culture chambers, and integrated valves allow researchers for long-term experiments with real-time monitoring under more realistic conditions.

One of the most notable advancements in microfluidics techniques is the development of organ-on-a-chip platforms, where living cells are cultured in engineered channels and recreate the structure and function of specific organs. For example, Heart-on-a-chip models can reproduce contraction and electrical signaling, lung-on-a-chip devices can simulate breathing, and liver-on-a-chip systems can maintain metabolic functions. By replicating mechanical forces, chemical gradients, and three-dimensional structure, these platforms are able to provide the more accurate, organ-specific data, enabling identification of potential drugs and reducing the risk of side effects [22].

Absorption, distribution, metabolism, excretion and toxicity (ADMET) study is one of the important aspects in drug development. Traditionally, these studies use lab-based cell tests, animal experiments, and computer models. However, each approach has its limits. Results from animals often do not translate well to humans, and static lab tests cannot show how different organs interact with each other in real time [23].

3.5. Microfluidics in 3D Bioprinting

When combined with 3D bioprinting, microfluidics takes tissue engineering to the next level. The process starts with bioprinting of tissue constructs that have precise shapes, arrangements, and have supporting materials, such as soft hydrogels for delicate tissues or stronger polymers for rigid structures. These printed tissues provide different cell type arrangement just like in the body. For example, liver tissue might contain both hepatocytes and endothelial cells, while cardiac tissue composed with cardiomyocytes and fibroblasts.

Once it printed, these tissues are placed on microfluidic chip, provides miniature life-support system. Tiny channels of microfluidics system control the flow of nutrient-rich culture medium, supply oxygen as well as remove waste, which create a more realistic model for study. By integrating the multiple printed tissues on one chip, researchers can create interconnected "mini-organs" that able to communicate with each other, closely representing organs interaction inside the human body system [24].

This integration makes it possible to study complex biological processes, test drugs more accurately, and even design patient-specific therapies, all in a controlled, scalable, and animal-free environment.

3.6. Microfluidics in CRISPR Base Application

Microfluidics has become a revolutionary method for improving CRISPR-based genome editing by making it possible to miniaturize, automate, and run multiple molecular workflows at the same time. Microfluidics together with CRISPR/Cas systems makes it possible to do high-throughput strain engineering, quick diagnostics, and optimize metabolic pathway by using small amount of reagents and getting better results. One such examples is the droplet-based microfluidic platform developed by [25]. It has a 10 × 10 reaction array with individually addressable electrodes that can do two important on-chip tasks: one is electrowetting to mix droplets with different reagents on demand, and second is the electroporation to quickly get CRISPR/Cas components into cells. This system can handle up to 100 transformations at the same time and works better than traditional cuvette-based methods when compare in term of scalability and compatibility with automated liquid-handling systems.

The platform uses CRMAGE technique, which is a combination of CRISPR/Cas9 and λ Red recombineering protein, to make genome editing more efficient. In proof-of-concept experiments, the *galK* gene in *Escherichia coli* was successfully disrupted with a success rate more than 98%, achieving traditional benchtop performance while need less human work. It also improves the metabolic pathway of an *Escherichia coli* strain that makes indigoidine, a naturally occurring blue pigment. Thus, this technology can be applied for many types of genome engineering tasks because each reaction chamber can be set up to work with different transformation conditions, and separated wells prevent cross-contamination [25].

Beyond genome editing, the coupling of microfluidics with CRISPR is proving highly valuable for rapid, point-of-care diagnostics. CRISPR–Cas12 and Cas13 systems have been integrated with droplet-based or paper-based microfluidics to enable nucleic acid detection of pathogens such as SARS-CoV-2 and Zika virus in under an hour. Droplet microfluidics also facilitates single-cell encapsulation, allowing pooled

CRISPR screens for functional genomics, while on-chip electroporation improves editing efficiency and preserves cell viability compared to bulk methods. Current chips are capable of handling 100 reactions, but the same Design, Principles could be scaled to more than 1,000 sites per wafer, significantly accelerating the design–build–test–learn cycle.

In addition to genome editing, the combination of CRISPR and microfluidics is showing great promise for quick, point-of-care diagnostics. It detects nucleic acids of pathogens like SARS-CoV-2 and the Zika virus within hour by using CRISPR Cas12 and Cas13 systems, combined with droplet-based or paper-based microfluidics [26, 27]. Droplet microfluidics system also facilitates single-cell encapsulation, allowing pooled CRISPR screens for functional genomics, while on-chip electroporation improves editing efficiency and preserves cell viability compared to bulk methods.

4. Comparative Analysis of Microfluidics with Traditional Techniques

By using small fluid volumes that provide a high surface-to-volume ratio, microfluidic platforms improve time efficiency by performing the quick analyses and reactions. This arrangement significantly reduces experimental turnaround times by enabling efficient thermal dynamics and rapid molecular diffusion. Furthermore, when compared to traditional culture systems, the microscale environment accelerates cellular and physiological responses because it closely resembles *in vivo* conditions. Faster experimental workflows also shorten the incubation times needed for many tests. According to studies, these benefits result from the fine control over microenvironmental elements that microfluidic designs provide [28].

5. Microfluidics: Key Challenges and Limitations

Although microfluidics has the potential to bring revolutionary changes to biomedical research, there are certain limitations that need to be overcome to make it more effective.

One major limitation is that compatibility of selected material. For instance, polydimethylsiloxane (PDMS), a ubiquitous material in microfluidics systems tends to absorb small hydrophobic molecules, which can change the solution concentrations and affect assay outcomes. Additionally, PDMS also swell when exposed to many organic solvents, leading to deformation and unreliable device behaviour.

One of the major concerns associated is standardization and reproducibility. The field lacks uniform fabrication protocols, which leads to variations across labs, making it complex in comparison and reliability.

Another challenge that still needs to worked out, when we moving from prototypes to scale-up and manufacturing. Standardized manufacturing processes, reproducibility, and cost efficiencies are necessary to maintain the microscale precision required in device designs while permitting scalable production. Last but not least, which create obstacles to clinical translation include the requirement for thorough validation, regulatory clearance, and smooth integration into current healthcare processes [29].

6. Future Directions

Future directions in microfluidics must focus on creating smarter systems that can adjust themselves in real time through feedback control. It includes development of more precise sensors that monitor fluid flow, temperature, or chemical changes, and also automatically make adjustments to maintain optimal conditions. These advancements in microfluidics will reduce errors and make experiments more reliable, especially in disease diagnosis and drug testing. Another promising area is the role of microfluidics in personalized medicine, which uses tiny amounts of patient samples for analysis. However, moving from lab prototypes to market product needs to addressed the regulatory hurdles, to make it more practical [30]. Overall, microfluidics systems are like a pandora's box, which holds countless commercial potential, but challenges like scaling up production and controlling costs will need to be overcome to fully realize its benefits.

7. CONCLUSIONS

Microfluidics has emerged as evolutionary platform that have ability to bridges the gap between *in vitro* experimentation and physiological complexity. Their interdisciplinary nature and ability to recreate dynamic, organ-level microenvironments on a chip makes it more reliable disease prediction models, with less dependency on animal testing, with faster, cost-effective drug discovery potential. By offering unparalleled control over fluidic and cellular conditions, it not only improves experimental precision but also supports the shift toward personalized medicine. However, many challenges such as optimizing material properties, large-scale production, and unavailability of proper guidelines and standardized protocols must be addressed to achieved their full clinical and commercial potential. The future also more focus on integration with advanced technologies such as AI, robotics, and 3D bioprinting to create intelligent, automated systems capable of high-throughput, real-time analysis. As these innovations mature, microfluidic systems are expected to transform the biomedical research and diagnostics system, bringing laboratory-grade capabilities directly to the patients.

Abbreviation

COVID-19: Coronavirus disease 2019
CRISPR: Clustered regularly interspaced short palindromic repeats
PDMS: Polydimethylsiloxane

PMMA: Polymethyl methacrylate
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
scRNA-seq: single-cell RNA sequencing
TB: Tuberculosis

REFERENCES

1. Niculescu AG, Chircov C, Bîrcă AC, Grumezescu AM. Fabrication and applications of microfluidic devices: A review. International journal of molecular sciences. 2021 Feb 18;22(4):2011.
2. Terry SC, Jerman JH, Angell JB. A gas chromatographic air analyzer fabricated on a silicon wafer. IEEE transactions on electron devices. 1979 Dec 31;26(12):1880-6.
3. Manz A, Graber N, Widmer HM. Miniaturized total chemical analysis systems: a novel concept for chemical sensing. Sensors and actuators B: Chemical. 1990 Jan 1;1(1-6):244-8.
4. Nielsen JB, Hanson RL, Almughamsi HM, Pang C, Fish TR, Woolley AT. Microfluidics: innovations in materials and their fabrication and functionalization. Analytical chemistry. 2019 Nov 13;92(1):150-68.
5. Zhang Z, Nagrath S. Microfluidics and cancer: are we there yet?. Biomedical microdevices. 2013 Aug;15(4):595-609.
6. Akbari Kenari M, Rezvani Ghomi E, Akbari Kenari A, Arabi SM, Deylami J, Ramakrishna S. Biomedical applications of microfluidic devices: Achievements and challenges. Polymers for Advanced Technologies. 2022 Dec;33(12):3920-34.
7. McDonald JC, Duffy DC, Anderson JR, Chiu DT, Wu H, Schueller OJ, Whitesides GM. Fabrication of microfluidic systems in poly (dimethylsiloxane). ELECTROPHORESIS: An International Journal. 2000 Jan 1;21(1):27-40.
8. James M, Revia RA, Stephen Z, Zhang M. Microfluidic synthesis of iron oxide nanoparticles. Nanomaterials. 2020 Oct 23;10(11):2113.
9. Damodara S, Shahriari S, Wu WI, Rezai P, Hsu HH, Selvaganapathy R. Materials and methods for microfabrication of microfluidic devices. In Microfluidic devices for biomedical applications 2021 Jan 1 (pp. 1-78). Woodhead Publishing.
10. Aghamiri S, Rabiee N, Ahmadi S, Rabiee M, Bagherzadeh M, Karimi M. Microfluidic devices: Synthetic approaches. InBiomedical Applications of Microfluidic Devices 2021 Jan 1 (pp. 23-36). Academic Press.
11. Leyerle BJ, LoBue M, Shabot MM. The PDMS as a focal point for distributed patient data. International Journal of Clinical Monitoring and Computing. 1988 Sep;5(3):155-61.
12. Sebastian Cabeza V. Chapter High and Efficient Production of Nanomaterials by Microfluidic Reactor Approaches.
13. Sticker D, Geczy R, Hafeli UO, Kutter JP. Thiol–ene based polymers as versatile materials for microfluidic devices for life sciences applications. ACS applied materials & interfaces. 2020 Feb 12;12(9):10080-95.
14. Harris P, Kaveh J, Kemas AM, Mikaelsson H, Fielden M, Lauschke VM, Zandi Shafagh R. Robust and Seamless Integration of Thiol-Ene-Epoxy Thermosets with Thermoplastics and Glass as Hybrid Microfluidic Devices Suitable for Drug Studies. Advanced Materials Interfaces. 2024 May;11(14):2300972.
15. Ren K, Zhou J, Wu H. Materials for microfluidic chip fabrication. Accounts of chemical research. 2013 Nov 19;46(11):2396-406.
16. Schaumburg F, Berli CL. Assessing the rapid flow in multilayer paper-based microfluidic devices. Microfluidics and Nanofluidics. 2019 Aug;23(8):98.
17. Zhang J, Wei X, Zeng R, Xu F, Li X. Stem cell culture and differentiation in microfluidic devices toward organ-on-a-chip. Future science OA. 2017 May 1;3(2): FSO187.
18. Zhou WM, Yan YY, Guo QR, Ji H, Wang H, Xu TT, Makabel B, Pilarsky C, He G, Yu XY, Zhang JY. Microfluidics applications for high-throughput single cell sequencing. Journal of nanobiotechnology. 2021 Oct 11;19(1):312.
19. Farhang Doost N, Srivastava SK. A comprehensive review of organ-on-a-chip technology and its applications. Biosensors. 2024 May 1;14(5):225.
20. Hargrove-Grimes P, Low LA, Tagle DA. Microphysiological systems: What it takes for community adoption. Experimental Biology and Medicine. 2021 Jun;246(12):1435-46.
21. Ahn J, Sei YJ, Jeon NL, Kim Y. Tumor microenvironment on a chip: the progress and future perspective. Bioengineering. 2017 Jul 21;4(3):64.
22. Rezaei Kolahchi A, Khadem Mohtaram N, Pezeshgi Modarres H, Mohammadi MH, Geraili A, Jafari P, Akbari M, Sanati-Nezhad A. Microfluidic-based multi-organ platforms for drug discovery. Micromachines. 2016 Sep 8;7(9):162.
23. An F, Qu Y, Luo Y, Fang N, Liu Y, Gao Z, Zhao W, Lin B. A laminated microfluidic device for comprehensive preclinical testing in the drug ADME process. Scientific reports. 2016 Apr 28;6(1):25022.
24. De Spirito M, Palmieri V, Perini G, Papi M. Bridging the gap: integrating 3D bioprinting and microfluidics for advanced multi-organ models in biomedical research. Bioengineering. 2024 Jun 28;11(7):664.
25. Iwai K, Wehrs M, Garber M, Sustarich J, Washburn L, Costello Z, Kim PW, Ando D, Gaillard WR, Hillson NJ, Adams PD. Scalable and automated CRISPR-based strain engineering using droplet microfluidics. Microsystems & nanoengineering. 2022 Mar 15;8(1):31.
26. Li SY, Cheng QX, Wang JM, Li XY, Zhang ZL, Gao S, Cao RB, Zhao GP, Wang J. CRISPR-Cas12a-assisted nucleic acid detection. Cell discovery. 2018 Apr 24;4(1):20.

27. Ning B, Yu T, Zhang S, Huang Z, Tian D, Lin Z, Niu A, Golden N, Hensley K, Threeton B, Lyon CJ. A smartphone-read ultrasensitive and quantitative saliva test for COVID-19. Science advances. 2021 Jan 8;7(2): eabe3703.
28. Wong Hawkes SY, Chapela MJ, Montembault M. Leveraging the advantages offered by microfluidics to enhance the drug discovery process. QSAR & Combinatorial Science. 2005 Aug;24(6):712-21.
29. Lee CS. Grand challenges in microfluidics: a call for biological and engineering action. Frontiers in Sensors. 2020 Sep 4; 1:583035.
30. Apoorva S, Nguyen NT, Sreejith KR. Recent developments and future perspectives of microfluidics and smart technologies in wearable devices. Lab on a Chip. 2024;24(7):1833-66.